REGENXBIO Inc. (RGNX) announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Kenneth Mills will step down as President and Chief Executive Officer, and is taking on an expanded role on the Board as Chairman.
Also, Board member Daniel Tassé has been appointed as REGENXBIO's Lead Independent Director, a role previously held by Jerry Karabelas. Karabelas and Co-Founder Allan Fox, who has served as Chairman since 2020, will remain on the Board.
The company reiterated its financial guidance previously provided on May 8, 2024: REGENXBIO expects balance in cash, cash equivalents and marketable securities of $380.5 million as of March 31, 2024 to fund its operations into 2026.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com